IRE1α mediates PKR activation in response to Chlamydia trachomatis infection

Published version
Repository DOI

Change log
Authors
Webster, Steve J 
Ellis, Lou 
O'Brien, Louise M 
Tyrrell, Beatrice 
Fitzmaurice, Timothy J 
Abstract

Protein kinase RNA activated (PKR) is a crucial mediator of anti-viral responses but is reported to be activated by multiple non-viral stimuli. However, mechanisms underlying PKR activation, particularly in response to bacterial infection, remain poorly understood. We have investigated mechanisms of PKR activation in human primary monocyte-derived dendritic cells in response to infection by Chlamydia trachomatis. Infection resulted in potent activation of PKR that was dependent on TLR4 and MyD88 signalling. NADPH oxidase was dispensable for activation of PKR as cells from chronic granulomatous disease (CGD) patients, or mice that lack NADPH oxidase activity, had equivalent or elevated PKR activation. Significantly, stimulation of cells with endoplasmic reticulum (ER) stress-inducing agents resulted in potent activation of PKR that was blocked by an inhibitor of IRE1α RNAse activity. Crucially, infection resulted in robust IRE1α RNAse activity that was dependent on TLR4 signalling whilst inhibition of IRE1α RNAse activity prevented PKR activation. Finally, we demonstrate that TLR4/IRE1α mediated PKR activation is required for the enhancement of interferon-β production following C. trachomatis infection. Thus, we provide evidence of a novel mechanism of PKR activation requiring ER stress signalling that occurs as a consequence of TLR4 stimulation during bacterial infection and contributes to inflammatory responses.

Description

This is the final version of the article. It first appeared from Elsevier via https://doi.org/10.1016/j.micinf.2016.03.010.

Keywords
PKR, ER stress, Chlamydia
Journal Title
Microbes and Infection
Conference Name
Journal ISSN
Volume Title
18
Publisher
Elsevier
Sponsorship
This work was supported by an MRC grant to JCG and JSHG, an Arthritis Research Senior Fellowship grant to JCG, the NIHR Cambridge Biomedical Research Centre and Cambridge Arthritis Research Endeavour (CARE).